Laddar...
Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
BACKGROUND: Treatment of patients with Cystic Fibrosis homozygous for the Phe508del gene, with Lumacaftor /Ivacaftor (LUM/IVA) improves outcomes in patients with FEV1 > 40% predicted. We set out to observe the most sensitive clinical measure that would change with treatment in terms of exercise c...
Sparad:
| I publikationen: | BMC Pulm Med |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6580585/ https://ncbi.nlm.nih.gov/pubmed/31208380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-019-0866-y |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|